AB - International Health Care Portfolio A Acc

Equity fund

1 year

Region

USA

Largest region

Medium

Risk

Cost

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Description

  • Under normale omstendigheter investerer Fondet i hovedsak i aksjer fra utstedere i helsesektoren og tilhørende bransjer. Formålet er å investere i verdipapirer som har potensial til å oppnå fremragende inntjeningsvekst. Det kan investere i aksjer i selskaper hvor som helst i verden, inklusiv i vekstland. Fondet kan benytte derivater (i) for effektiv porteføljeforvaltning og (ii) i arbeidet med å redusere potensielle risiko.

Investment horizon

  • AB - International Health Care Portfolio A Acc is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • Price/NAV

    05 Jun 2025

  • Start date
    04 Jul 1995
  • ISIN
    LU0058720904

Risk

  • Medium (4 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Costs

  • Ongoing costs

    Includes management fees of 1,76 %

  • Platform fee
  • Kickback fee
  • Annual running costs
  • Performance-based fee
  • Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.

Allocation

  • Stocks 100%
    Interest 0%

Portfolio

Shows the fund's largest investments.

  • Eli Lilly and Co
    10.6%
  • Johnson & Johnson
    7.6%
  • Roche Holding AG
    6.8%
  • UnitedHealth Group Inc
    6.8%
  • Gilead Sciences Inc
    5.1%
  • Cencora Inc
    4.5%
  • Intuitive Surgical Inc
    4.5%
  • Vertex Pharmaceuticals Inc
    4.4%
  • Novartis AG Registered Shares
    3.7%
  • Novo Nordisk AS Class B
    3.4%